Prialt (Ziconotide) In Severe Chronic Pain
Elan Pharmaceuticals · Pain
Phase 3
Completed
220
2015-12
Industry sponsor intelligence
Elan PharmaceuticalsClinical Pipeline.
Lead-sponsor view of Elan Pharmaceuticals's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 0
- Avg enrollment
- 260
Pipeline overview
Programs by phase and activity.
Velocity
Elan Pharmaceuticals trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 10
Phase 20
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Ziconotide → | 2 | 0 | 0 | 2 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain
Elan Pharmaceuticals · Pain
Phase 3
Completed
300
2015-12
Search sponsor records
All Elan Pharmaceuticals studies.
This page groups studies where Elan Pharmaceuticals is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first